Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669.
The recent development of immunotherapies to treat cancer has transformed the way that clinicians think about managing their patients with many forms of malignancies. The speed at which basic science and clinical trial information continue to emerge in this area, however, creates practice and/or educational gaps for busy clinicians who strive to maintain state-of-the art care for their patients with cancer. This field is one of the most clinically relevant and exciting areas of novel drug development in oncology.
“But how do I use this information to manage my patients with cancer?”
This is the key question, and the one whose answer ultimately means the most for your patients. The 4th Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application will answer that question. This exciting and fast-paced congress will provide a multi-module, curriculum-based program that focuses exclusively on immunotherapies and their application to the management of cancer. This intensive, 1-day interactive program will provide a comprehensive review of the key data sets that are most relevant to the application of these novel strategies for the clinician who manages some of the most difficult-to-treat forms of cancer. The program will focus on the practical application of recent clinical trial results that have shaped current and evolving clinical management, evolving biomarker information, the latest basic science findings, and the most highly anticipated clinical trials in the field.
Topics of particular interest will be optimal timing of checkpoint inhibitors, identification of patients with cell surface expression of a target antigen who would be good candidates for CAR T-cell treatment, using combination immunotherapies in patients with driver mutations (eg, EGFR/ALK), and the use of combination therapies targeting the IDO pathway in patients with advanced melanoma.
This educational program is directed toward oncologists, nurses, and pharmacists. Participants will be primarily those whose practice requires mastery and a critical understanding of the fundamental principles, pivotal published studies, and emerging information on immunotherapies and their evolving roles in the treatment of patients with cancer.
Upon successful completion of this educational activity, you should be better prepared to:
Cancer Summaries and Commentaries™: Update from Atlanta – Advances in the Treatment of Multiple Myeloma
Feb 28, 2019
Feb 28, 2019
Feb 28, 2019
23rd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
February 28, 2019 - March 3, 2019